Perfil
Timothy Kieffer is Chief Scientific Officer at Aardvark Therapeutics, Inc. since 2025.
Formerly, Dr. Kieffer was Chief Scientific Officer at Fractyl Health, Inc., Chief Scientific Officer at ViaCyte, Inc. from 2021 to 2022, and Professor at the University of British Columbia.
Dr. Kieffer earned a doctorate from the University of British Columbia.
Cargos activos de Timothy Kieffer
| Empresas | Cargo | Inicio |
|---|---|---|
| AARDVARK THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 20/05/2025 |
Antiguos cargos conocidos de Timothy Kieffer.
| Empresas | Cargo | Fin |
|---|---|---|
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology Develops transformative medicines for people with serious diseases | Director Técnico/Científico/I+D | 01/10/2022 |
University of British Columbia
University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| FRACTYL HEALTH, INC. | Director Técnico/Científico/I+D | - |
Formación de Timothy Kieffer.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 4 |
|---|---|
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology Develops transformative medicines for people with serious diseases | Health Technology |
University of British Columbia
University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fractyl Health, Inc.
Fractyl Health, Inc. BiotechnologyHealth Technology Develops and sells therapeutics for metabolic diseases, type 2 diabetes & obesity | Health Technology |
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel small molecule therapeutics for obesity and metabolic diseases | Health Technology |
- Bolsa de valores
- Insiders
- Timothy Kieffer
















